Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Tryptamine Therapeutics ( (AU:ENP) ) is now available.
Tryptamine Therapeutics, operating through Entropy Neurodynamics Limited, is a psychedelic-focused biotechnology company developing novel neurotherapeutics for mental health indications. Director Jason Carroll strengthened his alignment with shareholders by purchasing 1 million ordinary shares on market for A$30,000, lifting his direct holding to 53.3 million shares while retaining his extensive suite of performance and incentive options, signaling confidence in the company’s trajectory amid its continuing capital structure commitments.
The most recent analyst rating on (AU:ENP) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Average Trading Volume: 2,525,760
Technical Sentiment Signal: Sell
Current Market Cap: A$49.95M
Find detailed analytics on ENP stock on TipRanks’ Stock Analysis page.